Search Result

Search Result

Results for "

atherosclerotic plaque

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (3) Biochemical Assay Reagents (1) Endogenous Metabolite (2) Fluorescent Dye (1) Formyl Peptide Receptor (FPR) (1) Interleukin Related (1) Liposome (4) MMP (2) NO Synthase (2) p38 MAPK (2) PCSK9 (1) PGE synthase (1) Prostaglandin Receptor (1) Pyroptosis (1) Reactive Oxygen Species (ROS) (1) Sirtuin (2) Toll-like Receptor (TLR) (2)
By Research Areas:	Cancer (3) Cardiovascular Disease (13) Inflammation/Immunology (3) Metabolic Disease (4) Neurological Disease (4)
Oligonucleotides:	CpG ODNs (2)

19

Inhibitors & Agonists

1

Fluorescent Dye

4

Biochemical Assay Reagents

1

Peptides

3

Natural
Products

2

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

E1231 1 Publications Verification 1-{4-[2-(5-Methylfuran-2-yl)quinoline-4-carbonyl]piperazin-1-yl}ethan-1-one	Sirtuin	Cardiovascular Disease
E1231 is an orally active activator of Sirtuin 1 (SIRT1) (EC₅₀=0.83 μM), to modulate cholesterol and lipid metabolism. E1231 interactes with SIRT1 (K_D=9.61 μM) and deacetylated liver X receptor-alpha (LXRα), and increases ATP-binding cassette transporter A1 (ABCA1) expression. E1231 also reduces atherosclerotic plaque development in ApoE ^-/- mice model. E1231 can be used for research in cholesterol and lipid disorder-related diseases .

6-NBDG	Fluorescent Dye	Others
6-NBDG is a fluorescent glucose analogue, it can be used for fluorescence imaging and monitoring glucose transport and uptake. 6-NBDG can be used as a fluorescent probe for detecting macrophage-rich atherosclerotic plaques .

ONO-4817	MMP	Cardiovascular Disease
ONO-4817 is a potent inhibitor of matrix metalloproteinase (MMP). Inhibition of matrix metalloproteinases (MMPs) is expected to suppress atherosclerotic neointimal proliferation and thus limits atheromatous plaque progression. ONO-4817 suppresses the development of aortic intimal hyperplasia in experimental hyperlipidemic rabbit .

T0080	Formyl Peptide Receptor (FPR) Apoptosis Reactive Oxygen Species (ROS) Interleukin Related	Cardiovascular Disease
T0080 is a FPR-1 antagonist. T0080 reduces the cell apoptosis, inhibits ROS production and pro-inflammatory cytokines (TNF-α and IL-1β) from plaque macrophages, which attenuates atherosclerotic progression in ApoE ^−/− mice .

ZCDD083	Biochemical Assay Reagents	Others
ZCDD083 can be used as a positron emission tomography (PET) tracer for atherosclerotic plaques imagination, when labeled with ¹⁸F isotope .

Prostaglandin D synthase	PGE synthase	Cardiovascular Disease Cancer
Prostaglandin D synthase is a biomarker for meningioma cells and coronary artery disease. Lipocalin-type Prostaglandin D synthase (L-PGDS) is present in the atherosclerotic plaque of the human coronary artery and can be detectable in human serum .

DSPE-PEG3400-PP1	Liposome	Neurological Disease
DSPE-PEG3400-PP1 is a PEG compound which composed of DSPE and a PP1 peptide. PP1 peptide targets the inflammatory atherosclerotic plaque. DSPE-PEG3400-PP1 can be used for drug delivery .

DSPE-PEG5000-PP1	Liposome	Neurological Disease
DSPE-PEG5000-PP1 is a PEG compound which composed of DSPE and a PP1 peptide. PP1 peptide targets the inflammatory atherosclerotic plaque. DSPE-PEG5000-PP1 can be used for drug delivery .

DSPE-PEG2000-PP1	Liposome	Neurological Disease
DSPE-PEG2000-PP1 is a PEG compound which composed of DSPE and a PP1 peptide. PP1 peptide targets the inflammatory atherosclerotic plaque. DSPE-PEG2000-PP1 can be used for drug delivery .

DSPE-PEG1000-PP1	Liposome	Neurological Disease
DSPE-PEG1000-PP1 is a PEG compound which composed of DSPE and a PP1 peptide. PP1 peptide targets the inflammatory atherosclerotic plaque. DSPE-PEG1000-PP1 can be used for drug delivery .

ODN 1826 sodium 3 Publications Verification CpG 1826 sodium	Toll-like Receptor (TLR) Apoptosis NO Synthase	Cardiovascular Disease Inflammation/Immunology Cancer
ODN 1826 sodium is a class B CpG ODN (oligodeoxynucleotide) and TLR9 agonist. ODN 1826 sodium induces NO and iNOS production and enhances Apoptosis. ODN 1826 sodium enhances immune surveillance. ODN 1826 sodium increases aortic atherosclerotic plaque size. ODN 1826 sodium has antitumor activity against lung cancer, glioma and melanoma .

ODN 1826 3 Publications Verification CpG 1826	Toll-like Receptor (TLR) Apoptosis NO Synthase	Cardiovascular Disease Inflammation/Immunology Cancer
ODN 1826 is a class B CpG ODN (oligodeoxynucleotide) and TLR9 agonist. ODN 1826 induces NO and iNOS production and enhances Apoptosis. ODN 1826 enhances immune surveillance. ODN 1826 increases aortic atherosclerotic plaque size. ODN 1826 has antitumor activity against lung cancer, glioma and melanoma .

RXP470.1 RXP-470	MMP	Cardiovascular Disease
RXP470.1 (RXP-470) is a potent, selective MMP-12 inhibitor with a K_i of 0.2 nM against human MMP-12. RXP470.1 is 2 to 4 orders of magnitude less potent against other MMPs. RXP470.1 significantly reduces atherosclerotic plaque cross-sectional area in mouse. RXP470.1 results in less complex plaques with increased smooth muscle cell:macrophage ratio, less macrophage apoptosis, increased cap thickness, smaller necrotic cores, and decreased incidence of calcification .

GI-Y2	Pyroptosis	Cardiovascular Disease
GI-Y2 is an inhibitor of GSDMD and can inhibit Pyroptosis of macrophages induced by oxidized low-density lipoprotein (ox-LDL). In vivo, GI-Y2 can dose-dependently reduce atherosclerotic plaques in ApoE-/- mice and decrease the lesion size and fibrosis degree of the aortic root. GI-Y2 is expected to be used in the research of pyroptosis and cardiovascular diseases, such as atherosclerosis .

PCSK9-IN-10	PCSK9	Cardiovascular Disease Metabolic Disease
PCSK9-IN-10 is a potent and orally active PCSK9 inhibitor with an IC₅₀ value of 6.4 µM. PCSK9-IN-10 increases the expression of LDLR protein and decreases the expression of PCSK9. PCSK9-IN-10 reduces atherosclerosis progression. PCSK9-IN-10 has the potential for the research of hyperlipidemia .

DG-041 2 Publications Verification	Prostaglandin Receptor	Cardiovascular Disease
DG-041 is a potent, high affinity and selective EP₃ receptor antagonist with IC₅₀s of 4.6 nM and 8.1 nM in the binding and FLIPR assay, respectively. DG-041 inhibits PGE2 facilitation of platelet aggregation. DG-041 crosses the blood-brain barrier .

7-Ketocholesterol 1 Publications Verification	Endogenous Metabolite p38 MAPK	Cardiovascular Disease Metabolic Disease
7-Ketocholesterol is an oxidation product of cholesterol, widely present in atherosclerotic plaques, and has a stronger atherogenic effect than cholesterol. 7-Ketocholesterol can inhibit the rate-limiting enzymes involved in bile acid and cholesterol synthesis, such as cholesterol 7α-hydroxylase and HMG-CoA reductase. 7-Ketocholesterol exhibits pro-inflammatory effects both in vivo and in vitro and can induce cell apoptosis (apoptosis) .

7-Ketocholesterol (Standard)	Endogenous Metabolite p38 MAPK	Cardiovascular Disease Metabolic Disease
7-Ketocholesterol (Standard) is the analytical standard of 7-Ketocholesterol. This product is intended for research and analytical applications. 7-Ketocholesterol is an oxidation product of cholesterol, widely present in atherosclerotic plaques, and has a stronger atherogenic effect than cholesterol. 7-Ketocholesterol can inhibit the rate-limiting enzymes involved in bile acid and cholesterol synthesis, such as cholesterol 7α-hydroxylase and HMG-CoA reductase. 7-Ketocholesterol exhibits pro-inflammatory effects both in vivo and in vitro and can induce cell apoptosis (apoptosis) .

5-Heptadecylresorcinol 5-n-Heptadecylresorcinol; AR-C17	Sirtuin	Cardiovascular Disease Metabolic Disease
5-Heptadecylresorcinol (AR-C17), a phenolic lipid component, is also an orally active mitochondrial protector. 5-Heptadecylresorcinol improves mitochondrial function via sirtuin3 signaling pathway, thus alleviates endothelial cell damage and apoptosis. 5-Heptadecylresorcinol induces sirtuin3-mediated autophagy. 5-Heptadecylresorcinol reduces the atherosclerotic plaques in the aortic root region of mice heart. 5-Heptadecylresorcinol can be used for research of atherosclerosis prevention and obesity .

Cat. No.	Product Name	Type

6-NBDG	Fluorescent Dyes/Probes
6-NBDG is a fluorescent glucose analogue, it can be used for fluorescence imaging and monitoring glucose transport and uptake. 6-NBDG can be used as a fluorescent probe for detecting macrophage-rich atherosclerotic plaques .

Cat. No.	Product Name	Type

DSPE-PEG3400-PP1	Drug Delivery
DSPE-PEG3400-PP1 is a PEG compound which composed of DSPE and a PP1 peptide. PP1 peptide targets the inflammatory atherosclerotic plaque. DSPE-PEG3400-PP1 can be used for drug delivery .

DSPE-PEG5000-PP1	Drug Delivery
DSPE-PEG5000-PP1 is a PEG compound which composed of DSPE and a PP1 peptide. PP1 peptide targets the inflammatory atherosclerotic plaque. DSPE-PEG5000-PP1 can be used for drug delivery .

DSPE-PEG2000-PP1	Drug Delivery
DSPE-PEG2000-PP1 is a PEG compound which composed of DSPE and a PP1 peptide. PP1 peptide targets the inflammatory atherosclerotic plaque. DSPE-PEG2000-PP1 can be used for drug delivery .

DSPE-PEG1000-PP1	Drug Delivery
DSPE-PEG1000-PP1 is a PEG compound which composed of DSPE and a PP1 peptide. PP1 peptide targets the inflammatory atherosclerotic plaque. DSPE-PEG1000-PP1 can be used for drug delivery .

Cat. No.	Product Name	Target	Research Area

F11R peptide TFA	Peptides	Inflammation/Immunology
F11R peptide TFA is a F11 receptor molecule. F11R peptide TFA inhibits anti-F11R antibody-induced platelet aggregation, and inhibits the adhesion of platelets to cytokine (TNFα and INF-γ)-inflammed endothelial cells. F11R peptide TFA can be used for research of atherosclerotic plaques and associated thrombotic disease .

Cat. No.	Product Name	Category	Target	Chemical Structure

7-Ketocholesterol 1 Publications Verification	Triterpenes Structural Classification Terpenoids Source classification Endogenous metabolite	Endogenous Metabolite p38 MAPK
7-Ketocholesterol is an oxidation product of cholesterol, widely present in atherosclerotic plaques, and has a stronger atherogenic effect than cholesterol. 7-Ketocholesterol can inhibit the rate-limiting enzymes involved in bile acid and cholesterol synthesis, such as cholesterol 7α-hydroxylase and HMG-CoA reductase. 7-Ketocholesterol exhibits pro-inflammatory effects both in vivo and in vitro and can induce cell apoptosis (apoptosis) .

5-Heptadecylresorcinol 5-n-Heptadecylresorcinol; AR-C17	Structural Classification Gramineae Source classification Secale cereale Phenols Polyphenols Plants	Sirtuin
5-Heptadecylresorcinol (AR-C17), a phenolic lipid component, is also an orally active mitochondrial protector. 5-Heptadecylresorcinol improves mitochondrial function via sirtuin3 signaling pathway, thus alleviates endothelial cell damage and apoptosis. 5-Heptadecylresorcinol induces sirtuin3-mediated autophagy. 5-Heptadecylresorcinol reduces the atherosclerotic plaques in the aortic root region of mice heart. 5-Heptadecylresorcinol can be used for research of atherosclerosis prevention and obesity .

7-Ketocholesterol (Standard)	Triterpenes Structural Classification Terpenoids Source classification Endogenous metabolite	Endogenous Metabolite p38 MAPK
7-Ketocholesterol (Standard) is the analytical standard of 7-Ketocholesterol. This product is intended for research and analytical applications. 7-Ketocholesterol is an oxidation product of cholesterol, widely present in atherosclerotic plaques, and has a stronger atherogenic effect than cholesterol. 7-Ketocholesterol can inhibit the rate-limiting enzymes involved in bile acid and cholesterol synthesis, such as cholesterol 7α-hydroxylase and HMG-CoA reductase. 7-Ketocholesterol exhibits pro-inflammatory effects both in vivo and in vitro and can induce cell apoptosis (apoptosis) .

Cat. No.	Product Name		Classification

ODN 1826 sodium 3 Publications Verification CpG 1826 sodium		CpG ODNs
ODN 1826 sodium is a class B CpG ODN (oligodeoxynucleotide) and TLR9 agonist. ODN 1826 sodium induces NO and iNOS production and enhances Apoptosis. ODN 1826 sodium enhances immune surveillance. ODN 1826 sodium increases aortic atherosclerotic plaque size. ODN 1826 sodium has antitumor activity against lung cancer, glioma and melanoma .

ODN 1826 3 Publications Verification CpG 1826		CpG ODNs
ODN 1826 is a class B CpG ODN (oligodeoxynucleotide) and TLR9 agonist. ODN 1826 induces NO and iNOS production and enhances Apoptosis. ODN 1826 enhances immune surveillance. ODN 1826 increases aortic atherosclerotic plaque size. ODN 1826 has antitumor activity against lung cancer, glioma and melanoma .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

MedChemExpress Magic Cece

MedChemExpress: Contact Us; About Us; Headquarters; Distributors; Statement on False Report; Careers

Customer Support: Technical Support; Service; Ordering Information; Easy Return; Shipping Rates & Policies; Intellectual Property Promise

Resources: Free Sample; Resources; Molarity Calculator; Dilution Calculator; Terms & Conditions; Reconstitution Calculator; Specific Activity Calculator; DNA/RNA sequence conversion tools

Subscribe to our E-newsletter

Name
Email *

	Sorry, but the email address you supplied was invalid.

Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.

Copyright © 2013-2025 MedChemExpress. All Rights Reserved.: Site Map Privacy Policy

Join with us